URIXMY Trademark

Trademark Overview

On Thursday, March 17, 2022, a trademark application was filed for URIXMY with the United States Patent and Trademark Office. The USPTO has given the URIXMY trademark a serial number of 97317607. The federal status of this trademark filing is REGISTERED as of Tuesday, February 6, 2024. This trademark is owned by GlaxoSmithKline Biologicals SA. The URIXMY trademark is filed in the Pharmaceutical Products category with the following description:

Pharmaceutical preparations for the treatment of infectious diseases, pain, inflammation, obesity and cognitive disorders; Vaccines
urixmy

General Information

Serial Number97317607
Word MarkURIXMY
Filing DateThursday, March 17, 2022
Status700 - REGISTERED
Status DateTuesday, February 6, 2024
Registration Number7296583
Registration DateTuesday, February 6, 2024
Mark Drawing4000 - Illustration: Drawing with word(s) / letter(s) / number(s) in Block form
Published for Opposition DateTuesday, November 21, 2023

Trademark Statements

Goods and ServicesPharmaceutical preparations for the treatment of infectious diseases, pain, inflammation, obesity and cognitive disorders; Vaccines
Translation of Words in MarkThe wording URIXMY has no meaning in a foreign language.

Classification Information

International Class005 - Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes; dietetic substances adapted for medical use, food for babies; plasters, materials for dressings; material for stopping teeth, dental wax; disinfectants; preparations for destroying vermin; fungicides, herbicides.
US Class Codes005, 006, 018, 044, 046, 051, 052
Class Status Code6 - Active
Class Status DateTuesday, March 22, 2022
Primary Code005
First Use Anywhere DateNOT AVAILABLE
First Use In Commerce DateNOT AVAILABLE

Trademark Owner History

Party NameGlaxoSmithKline Biologicals SA
Party Type30 - Original Registrant
Legal Entity Type99 - Other
AddressRixensart B-1330
BE
Party NameGlaxoSmithKline Biologicals SA
Party Type20 - Owner at Publication
Legal Entity Type99 - Other
AddressRixensart B-1330
BE
Party NameGlaxoSmithKline Biologicals SA
Party Type10 - Original Applicant
Legal Entity Type99 - Other
AddressRixensart B-1330
BE

Trademark Events

Event DateEvent Description
Tuesday, February 6, 2024NOTICE OF REGISTRATION CONFIRMATION EMAILED
Tuesday, February 6, 2024REGISTERED-PRINCIPAL REGISTER
Tuesday, November 21, 2023OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Tuesday, November 21, 2023PUBLISHED FOR OPPOSITION
Wednesday, November 1, 2023NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Wednesday, October 18, 2023CASE RETURNED TO EXAMINATION
Wednesday, October 18, 2023NOTICE OF ALLOWANCE CANCELLED
Tuesday, October 10, 2023JURISDICTION RESTORED TO EXAMINING ATTORNEY
Tuesday, October 10, 2023PETITION TO DIRECTOR - CHANGE BASIS - GRANTED
Wednesday, October 4, 2023ASSIGNED TO PETITION STAFF
Tuesday, September 19, 2023TEAS PETITION TO AMEND BASIS RECEIVED
Tuesday, July 18, 2023NOA E-MAILED - SOU REQUIRED FROM APPLICANT
Tuesday, May 23, 2023OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Tuesday, May 23, 2023PUBLISHED FOR OPPOSITION
Wednesday, May 3, 2023NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Wednesday, April 19, 2023APPROVED FOR PUB - PRINCIPAL REGISTER
Wednesday, April 19, 2023EXAMINER'S AMENDMENT ENTERED
Wednesday, April 19, 2023NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED
Wednesday, April 19, 2023EXAMINERS AMENDMENT E-MAILED
Wednesday, April 19, 2023EXAMINERS AMENDMENT -WRITTEN
Saturday, December 31, 2022NOTIFICATION OF NON-FINAL ACTION E-MAILED
Saturday, December 31, 2022NON-FINAL ACTION E-MAILED
Saturday, December 31, 2022NON-FINAL ACTION WRITTEN
Wednesday, December 28, 2022ASSIGNED TO EXAMINER
Wednesday, August 3, 2022TEAS CHANGE OF CORRESPONDENCE RECEIVED
Wednesday, August 3, 2022TEAS CHANGE OF DOMESTIC REPRESENTATIVES ADDRESS
Wednesday, August 3, 2022ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
Wednesday, August 3, 2022TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
Tuesday, March 22, 2022NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Monday, March 21, 2022NEW APPLICATION ENTERED

Related Keywords

urixmy obesity cognitive disorders vaccines inflammation pain preparations treatment infectious diseases